NasdaqCM - Delayed Quote • USD
Cyclacel Pharmaceuticals, Inc. (CYCC)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 4:48 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -4.56 | -3.44 | -13.38 | -24.37 |
| Low Estimate | -4.56 | -3.44 | -13.38 | -24.37 |
| High Estimate | -4.56 | -3.44 | -13.38 | -24.37 |
| Year Ago EPS | -7.05 | -6.6 | -26.75 | -13.38 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 1 | 1 | 1 | 1 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | 373k | 420k | -- |
| Sales Growth (year/est) | -- | -- | -- | -- |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -9.95 | -7.55 | -5.45 | -5.89 |
| EPS Actual | -7.05 | -6.6 | -7.35 | -6.23 |
| Difference | 2.9 | 0.95 | -1.9 | -0.34 |
| Surprise % | 29.10% | 12.60% | -34.90% | -5.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -4.56 | -3.44 | -13.38 | -24.37 |
| 7 Days Ago | -4.56 | -3.44 | -13.38 | -24.37 |
| 30 Days Ago | -5.92 | -5.98 | -15.67 | -24.37 |
| 60 Days Ago | -5.92 | -5.98 | -15.67 | -24.37 |
| 90 Days Ago | -5.92 | -5.98 | -15.67 | -24.37 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CYCC | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 35.30% | -- | -- | 0.80% |
| Next Qtr. | 47.90% | -- | -- | 9.60% |
| Current Year | 50.00% | -- | -- | 4.50% |
| Next Year | -82.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | -- | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Downgrade | Brookline Capital: Buy to Hold | 12/19/2023 |
| Maintains | Roth MKM: Buy to Buy | 12/19/2023 |
Related Tickers
NERV Minerva Neurosciences, Inc.
2.5000
+1.21%
TENX Tenax Therapeutics, Inc.
3.6800
+1.10%
IGMS IGM Biosciences, Inc.
7.41
-8.86%
SABS SAB Biotherapeutics, Inc.
4.4600
+0.45%
NRBO NeuroBo Pharmaceuticals, Inc.
3.4400
-0.58%
IPHA Innate Pharma S.A.
2.3500
-2.08%
BCAB BioAtla, Inc.
2.4300
-3.95%
ANEB Anebulo Pharmaceuticals, Inc.
2.8500
-1.38%
VCNX Vaccinex, Inc.
4.8000
-0.62%
CYTO Altamira Therapeutics Ltd.
1.5000
-0.66%